|Bid||67.50 x 1000|
|Ask||68.02 x 200|
|Day's Range||67.55 - 69.23|
|52 Week Range||36.10 - 71.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.40|
Stock Research Monitor: CGIX, CHEK, and EXAS LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on DXCM sign up now at www.wallstequities.com/registration . Today's research on WallStEquities.com ...
Demand for its colon cancer screening solution continues to drive sales higher even as the company invests in next-generation screening.
NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PDL ...
J. P. Morgan analysts recommended investors continue to overweight small-cap stocks, seeing them as shielded from the escalating risk of a trade war and U.S. dollar volatility
Exact Sciences broke out to a record high Wednesday after the biotech showed its newest blood test could detect curable liver cancer in 91% of patients studied.
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Laboratories & Research stocks: DexCom Inc. (NASDAQ: DXCM), Exact Sciences Corp. (NASDAQ: EXAS), iKang Healthcare Group Inc. (NASDAQ: KANG), and Invitae Corp. (NYSE: NVTA).
Shares jump after the American Cancer Society tweaks its recommended guidelines for cancer screening. Here's what investors need to know.
Exact Sciences Corp. , maker of a colon cancer test, had shares surge 11% in extremely heavy Wednesday trade after the American Cancer Society recommended screening for colon cancers starting five years earlier, at age 45.
After reading Exact Sciences Corporation’s (NASDAQ:EXAS) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past andRead More...
NEW YORK, May 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Boardwalk ...
MILWAUKEE and MADISON, Wis., May 3, 2018 /PRNewswire/ -- Colon cancer cut short the life of legendary football coach Vince Lombardi at the age of 57 and, nearly 50 years later, remains the number two cancer killer in the United States. Now, the foundation bearing his name and one of the country's premier cancer diagnostics companies are teaming up to fight back. Today, the Vince Lombardi Cancer Foundation (VLCF) announced a new, multi-year partnership with Madison, Wis.-based Exact Sciences that will work to increase awareness of colon cancer, stress the importance of screening and prevention, and raise funds for cancer research.
Exact Sciences CEO Kevin Conroy continues to see big growth from the company’s colon-cancer test. Conroy says Exact’s screen, Cologuard, could ultimately deliver revenue of $5 to $6 billion annually, more than 10 times projected 2018 sales, as physicians and U.S. consumers embrace it. “We have an attractive long-term opportunity given the size of the market and our position in it,” Conroy told Barron’s today.
MADISON, Wis., May 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences during May and invited investors to participate by webcast. The webcasts can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer.
- Nearly 9,000 healthcare providers ordered their initial Cologuard test during the first quarter, and more than 110,000 have ordered since the test was launched MADISON, Wis. , April 26, 2018 /PRNewswire/ ...
NEW YORK, NY / ACCESSWIRE / April 13, 2018 / U.S. markets jumped Thursday as investor's attention shifted from current geopolitical tensions to the upcoming earnings season. Bank stocks were the top gainers ...
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / U.S. markets rallied in early trading Monday on the strength of technology stocks and the easing of trade relations between the U.S. and China. However, most ...
MADISON, Wis., April 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company plans to release its first-quarter 2018 financial results after the close of the U.S. financial markets on April 26, 2018. Following the release, company management will host a webcast and conference call at 5 p.m. EDT to discuss financial results and business progress.